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Abstract
Background: Gene fusion events resulting from chromosomal rearrangements play an important role in initiation
of lung adenocarcinoma. The recent association of four oncogenic driver genes, ALK, ROS1, RET, and NTRK1, as lung
tumor predictive biomarkers has increased the need for development of up-to-date technologies for detection of
these biomarkers in limited amounts of material.
Methods: We describe here a multi-institutional study using the Ion AmpliSeq™ RNA Fusion Lung Cancer Research
Panel to interrogate previously characterized lung tumor samples.
Results: Reproducibility between laboratories using diluted fusion-positive cell lines was 100%. A cohort of lung
clinical research samples from different origins (tissue biopsies, tissue resections, lymph nodes and pleural fluid
samples) were used to evaluate the panel. We observed 97% concordance for ALK (28/30 positive; 71/70 negative
samples), 95% for ROS1 (3/4 positive; 19/18 negative samples), and 93% for RET (2/1 positive; 13/14 negative samples)
between the AmpliSeq assay and other methodologies.
Conclusion: This methodology enables simultaneous detection of multiple ALK, ROS1, RET, and NTRK1 gene fusion
transcripts in a single panel, enhanced by an integrated analysis solution. The assay performs well on limited amounts
of input RNA (10 ng) and offers an integrated single assay solution for detection of actionable fusions in lung
adenocarcinoma, with potential savings in both cost and turn-around-time compared to the combination of all
four assays by other methods.
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Background
Non-small cell lung carcinoma (NSCLC) has been
categorized into several distinct entities by molecular
characterization of genetic alterations occurring during
epithelial cell transformation. These alterations lead
mainly to the activation of oncogenes such as EGFR,
KRAS, NRAS, BRAF or ERBB2, [1–3] which occur
through point mutations, small deletions or insertions
and, more rarely, amplifications. Several other key
drivers have been implicated in lung cancer carcinogen-
esis through other mechanisms. Indeed, chromosomal
rearrangements involving the tyrosine kinase receptor
genes ALK, [4] ROS1, [5] RET, [6–8] and NTRK1, [9]
have been more recently described, extending the reper-
toire of molecular alterations found in NSCLC. These
fusion events, involving a variety of partner genes, result
in the formation of chimeric fusion kinases capable of
oncogenic transformation and induction of oncogene de-
pendency within the neoplastic cells. The prevalence of
each of these chromosomal rearrangements individually
is 1–7% in NSCLC [4, 6, 10, 11], and altogether can be
identified in approximately 5–9% of NSCLC [7, 12, 13].
The development of drugs that specifically target
fusion proteins encoded by these rearrangements [9, 11,
14] has driven the need for systematic sensitive assays to
detect them. Lung cancer fusions have traditionally been
detected using FISH, IHC, or RT-PCR. While FISH is
considered the gold standard, especially for ALK testing
due to the availability of an FDA-approved ALK FISH
assay, FISH analysis for multiple targets per sample can
be costly. The massively parallel nature of next gener-
ation sequencing (NGS) allows a rapid characterization
of point mutations, small insertions and deletions. Add-
itionally, NGS can be used for the detection of chromo-
some rearrangements in a large set of genes by targeted
sequencing of the fusion junctions or by paired-end
mapping methods. In this study we validated a new
library kit, the Ion AmpliSeq™ RNA Fusion Lung Cancer
Research Panel, for characterization of the most frequent
chromosome rearrangements in lung adenocarcinoma
by NGS. This library kit is based on the high-multiplex-
ing capabilities of PCR and focuses on the identification
of 72 different transcripts. We report the sensitivity and
specificity of this assay for the detection of gene fusions
implicated in NSCLC.
Methods
Samples
A total of 138 clinical research samples previously tested
for ALK, ROS1, and/or RET rearrangements were col-
lected from 10 participating laboratories. All clinical
research samples were studied in the laboratory of
origin. All samples were from resections or biopsies that
had been formalin-fixed and paraffin-embedded (FFPE),
with the exception of three fresh frozen samples (one
resection and two pleural effusions). These included 128
samples previously tested for ALK rearrangements by
fluorescence in situ hybridization (FISH). Sixty-five of
these samples had also been tested for ALK rearrange-
ments by another method: immunohistochemistry
(IHC), reverse transcription (RT)-PCR, and/or mass
spectrometry (performed on the MassARRAY System
from Agena Bioscience, San Diego, CA). Categorization
of the ALK-tested samples as positive, negative or incon-
clusive was determined by the FISH results, as this
methodology is considered the gold standard for ALK
testing. For those samples previously tested by multiple
methods, any discrepancies in results between the meth-
odologies were noted. Thirteen of the ALK samples had
also been tested for ROS1 and/or RET rearrangements.
An additional 10 clinical research samples previously
tested for ROS1 and/or RET, but for which ALK testing
results were unavailable, were also included in this study.
Categorization of the ROS1 and RET samples was based
on the results from any available method, including
FISH, IHC, RT-PCR and/or mass spectrometry, since
there is not an established gold-standard for detection of
these rearrangements.
RNA was extracted from each of the clinical research
samples by the participating laboratories using their
respective standard extraction procedures. Six of the ten
laboratories used the RecoverAll Total Nucleic Acid
Isolation Kit for FFPE (Thermo Fisher Scientific,
Waltham, MA); remaining labs used the Qiagen RNeasy
FFPE Kit (Qiagen, Hilden, Germany), the Qiagen AllPrep
DNA/RNA FFPE Kit, or the Maxwell LEV RNA FFPE
Purification Kit (Promega, Madison, WI). RNA was
quantified using the Qubit RNA assay kits (Thermo
Fisher) at eight of the laboratories; Quant-iT RiboGreen
RNA Assay Kit (Thermo Fisher) and the Nanodrop 2000
instrument (Thermo Scientific) were also used for
quantification.
In addition to the clinical research samples, a cocktail of
RNA isolated from the ALK fusion-positive H2228 (ATCC
CRL-5935), ROS1 fusion-positive HCC-78 (DSMZ ACC
563), and RET fusion-positive LC-2/ad (ECACC LC-2/ad)
cell lines was prepared by Thermo Fisher Scientific and
supplied to each of the participating laboratories. Select
laboratories also prepared and tested RNA isolated from
FFPE versions of these cell lines and RNA isolated from
the ALK fusion-positive cell line H3122 (ECACC
NCI-H322) and the NTRK1 fusion-positive cell line
KM-12.
Ion AmpliSeq RNA fusion lung Cancer research panel design
Primers spanning 72 fusions (37 ALK, 9 RET, 15 ROS1,
and 11 NTRK1) were designed by a research team at
Thermo Fisher. These primers were designed to span all
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previously described fusions, at the time of development,
for ALK, ROS1, RET, and NTRK1 in lung cancers.
Sources used for the curation of known fusions included
the COSMIC and NCBI databases, and review of current
medical literature. Targeted fusion genes are shown in
Table 1. The multiplex primer mix also included primers
for the amplification of five housekeeping genes: HMBS,
ITGB7, LMNA, MYC, and TBP.
Additionally, primers designed to amplify 5′ and 3′
regions of ALK, ROS1, RET, and NTRK1 were included
in the primer mix. Amplification of these regions for
each gene of interest allowed for the comparison of
expression levels between the 3′ end of the gene, which
is part of the resulting fusion, and the non-involved 5′
end of the gene. A list of all targets in the multiplex
PCR – including targeted fusions (genes and exons),
expression control genes, and 3′and 5′regions – is avail-
able in Additional file 1: Table S1.
Detection of fusions
A minimum of 10 ng of total RNA was reverse tran-
scribed using the SuperScript VILO cDNA Synthesis Kit
followed by library generation using the Ion AmpliSeq
Library Kit 2.0 and the Ion AmpliSeq RNA Fusion Lung
Cancer Research Panel (hereafter, AmpliSeq Fusion
Lung Panel). Barcodes were utilized during library
generation using the Ion Xpress Barcode Adapters.
Libraries were quantified using the Qubit DNA assay,
the 2100 BioAnalyzer (Agilent Technologies, Santa
Clara, CA) or the Ion Library Quantitation Kit, then
pooled in equimolar concentrations for sequencing.
Eight to sixteen libraries were multiplexed and tem-
plated using the Ion OneTouch2 System with the Ion
PGM Template OT2 200 Kit. Libraries were sequenced
using the Ion PGM Sequencing 200 v2 kit on an Ion 316
v2 or 318 v2 chip on the Ion PGM instrument. (All
reagents and instrumentation above are from Thermo
Fisher Scientific, with the exception of the BioAnalyzer.)
Typically, eight samples were sequenced per 316 chip
and sixteen samples per 318 chip.
After sequencing, unaligned BAM files were trans-
ferred to the Ion Reporter Software 4.2 and analyzed
using the AmpliSeq Lung Fusion single sample work-
flow. This workflow utilizes a BED file comprised of
chimeric sequences for targeted fusion transcripts along
with sequences for the expression control genes and the
3′and 5′regions of ALK, ROS1, RET, and NTRK1. The
alignment consists of three main steps. In the first step,
the aligner requires that the reads align end to end (i.e,
reads that are trimmed, or soft clipped, at the ends are
not allowed). Each read is then aligned to the best
primary alignment and filtering criteria are applied.
Alignments to the fusion targets are counted only if the
read overlaps at least 70% of the expected fusion insert
with high local alignment score. Alignments to the
imbalance and control targets are counted if the read
overlaps at least 50%. In the second step, all unaligned
reads, and reads that aligned but were filtered out, are
split into two fragments. These fragmented reads are
then re-aligned to the same reference file. Trimming of
the reads is allowed in this step and all the alignments of
every read (not just the primary alignments) are kept in
the alignments files. This step helps recover more counts
for the targets in the reference file and also finds any
non-targeted fusion isoforms that are not present in the
original list of targets. A novel fusion isoform involving
existing primers is reported in the output if there is
evidence from at least 100 different pairs of fragments.
Lastly, counts from steps one and two are aggregated
and all the fusion targets that have counts higher than
the threshold are reported as “fusion present.” The
algorithm generates a 3′/5′expression imbalance metric
for each of the driver genes based on the individual
counts of the 5′assay and 3′assay. It is calculated by
subtracting the count of 5′reads from the count of 3′
reads, and dividing the result by the sum of counts of all
control targets. This metric can be used to confirm the
detection of a known fusion or to predict a fusion in the
sample that is not covered by the isoforms in the panel.
Results
Cell lines
Using the cocktail of RNA from the ALK, ROS1, and
RET fusion-positive cell lines, each of the ten participat-
ing laboratories successfully detected all three rearrange-
ments using the AmpliSeq Fusion Lung Panel assay (see
Table 2). The fusions detected corresponded to the rear-
rangements previously described for these cell lines [11,
15–18] (see Table 3). The expected rearrangements were
also detected from RNA isolated from the FFPE cell
blocks of the same cell lines and from the ALK-positive
H3122 cell line [11] (Tables 2 and 3). In the KM12 cell
line [19], primers for the specific NTRK fusion were not
included in the assay design, but the rearrangement was
Table 1 Targeted Partners for ALK, RET, ROS1, and NTRK1
ALK RET ROS1 NTRK1
EML4 KIF5B CD74 CEL
KIF5B CCDC6 SDC4 NFASC
KLC1 CUX1 SLC34A2 IRF2BP2
HIP1 EZR TFG
TPR TPM3 SQSTM1
LRIG3 SSBP2
GOPC CD74
DYNC2H1
MPRIP
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detected by a positive 3′/5′imbalance result of 0.076,
above the cut-off of 0.025 (Table 2).
ALK clinical samples
Of the 138 clinical research samples tested, 117 (84.5%)
passed the QC requirement of a minimum of 20,000
total reads. One hundred of these samples had previ-
ously been tested for ALK rearrangements by FISH with
conclusive results; AmpliSeq Fusion Lung Panel results
were 97% concordant (97/100 samples) with FISH
analysis (see Table 4). ALK rearrangements were
detected in 28/30 ALK FISH-positive samples, with a
sensitivity of 93.3%; exact fusions were identified in 24
of the samples and an additional 4 samples showed
evidence of rearrangement using the 3′/5′imbalance
calculation. In samples negative for ALK rearrangements
by FISH, 69 of 70 samples were also negative by the
AmpliSeq assay, thus resulting in a specificity of 98.6%.
Details on all ALK clinical research samples are shown
in Additional file 1: Table S2.
Closer analysis of the discordant results (see
Table 5), revealed that two of the FISH-positive ALK
samples without a detected fusion showed 10%
rearranged cells (below the usual cut-off of 15%). One
of these samples showed only weak staining by IHC,
and subsequent re-testing by the AmpliSeq Fusion
Lung Panel gave a positive result of a fusion of
HIP1-ALK with 30 reads. Five of the remaining seven
discordant ALK FISH-positive samples showed an
atypical FISH result of one red signal, rather than the
split red-green signal; of these, two were IHC negative
for ALK and one was positive by IHC originally, but
negative upon repeat testing. The remaining two
FISH-positive, AmpliSeq fusion-negative samples
showed typical FISH results with 19% and 20% rear-
ranged cells, respectively, and both were positive for
ALK IHC staining.
One discordant sample was negative by FISH and
positive by AmpliSeq. This sample showed an EML4-
ALK fusion with 6137 fusion reads, and the 3′/5′im-
balance in this sample also showed a positive result.
Additionally, this sample had previously tested posi-
tive for ALK protein expression by IHC.
ROS1 and RET clinical samples
Panel results for ROS1 and RET were concordant in 21/
22 samples (95.5%) for ROS1 and 14/15 (93.3%) for RET
as compared to previous testing using available methods,
Table 2 Control Sample Results Across Participating Laboratories
Laboratory Sample ALK
fusion
ROS1
fusion
RET
fusion
NTRK1
fusion
ALK 3′/5′
imbalance
ROS1 3′/5′
imbalance
RET 3′/5′
imbalance
NTRK 3′/5′
imbalance
INSERM Cell Line RNA cocktaila Detected Detected Detected n/a 0.0044 0.3031 0.0603 n/a
Kinki Cell Line RNA cocktaila Detected Detected Detected n/a 0.0405 0.4648 0.0434 n/a
ARUP Cell Line RNA cocktaila Detected Detected Detected n/a 0.0172 0.6141 0.0421 n/a
ARC-Net Cell Line RNA cocktaila Detected Detected Detected n/a 0.0086 0.3458 0.0353 n/a
Viollier Cell Line RNA cocktaila Detected Detected Detected n/a 0.043 0.3398 0.046 n/a
Radboudumc Cell Line RNA cocktaila Detected Detected Detected n/a 0.0414 0.2502 0.0856 n/a
CROM Cell Line RNA cocktaila Detected Detected Detected n/a 0.012 0.054 0.0813 n/a
IPATIMUP Cell Line RNA cocktaila Detected Detected Detected n/a 0.0238 0.2877 0.0539 n/a
Warwick Cell Line RNA cocktaila Detected Detected Detected n/a 0.0064 0.3 0.055 n/a
Queen’s Cell Line RNA cocktaila Detected Detected Detected n/a 0.0123 0.4158 0.0478 n/a
ARUP FFPE cell block H2228 Detected n/a n/a n/a 0.0312 n/a n/a n/a
ARUP FFPE cell block HCC78 n/a Detected n/a n/a n/a 3.8313 n/a n/a
ARUP FFPE cell block LC-2/ad n/a n/a Detected n/a n/a n/a 0.2521 n/a
Kinki Fresh cells H3122 Detected n/a n/a n/a 0.3165 n/a n/a n/a
ARUP FFPE cell block KM-12 n/a n/a n/a Not covered n/a n/a n/a 0.076
aA mixture of RNA from three cell lines (H2228, HCC78, and LC-2/ad)
Table 3 Cell Line Fusions
Cell line Expected fusion (s) Detected fusion (s)
H2228 EML4(6a,6b)-ALK(20) EML4(6a,6b)-ALK(20)
HCC78 SLC34A2(4)-ROS1(32,34) SLC34A2(4)-ROS1(32,34,35,36)
LC-2/ad CCDC6(1)-RET(12) CCDC6(1)-RET(12)
H3122 EML4(13)-ALK(20) EML4(13)-ALK(20)
KM-12 TPM3(7)-NTRK1(8) not covered
Table 4 Concordance Between FISH and AmpliSeq for Detection
of ALK Fusions
FISH + FISH -
AmpliSeq + 28 1
AmpliSeq - 2 69
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including FISH, IHC, RT-PCR, and mass spectrometry.
The AmpliSeq assay detected the appropriate fusions in
3/4 ROS1-positive samples and in 1/1 RET-positive
sample. Samples previously determined to be negative
for ROS1 using other methodologies (18 samples) were
all negative using the AmpliSeq Fusion Lung Panel. In
samples previously determined to be negative for RET
fusions, 13 of 14 were negative by the AmpliSeq panel,
and one showed a positive imbalance result of 0.197, in
the absence of a detected fusion isoform (Additional file
1: Table S3). This sample was subsequently tested using
the RET FISH break-apart probe and also re-run using
the AmpliSeq panel; both results were negative.
Detection and confirmation of additional fusions
Testing of the clinical research samples yielded the
detection of ROS1 fusions in two samples which were
ALK-negative by FISH (Samples 63 and 67, Additional
file 1: Table S2). In both cases, the CD74-ROS1 fusion
was detected and subsequent testing using a TaqMan
assay with primers specific for the detected fusion
confirmed the results. Prior to this study, neither of
these samples had been tested for ROS1 rearrangements.
RET fusions were detected in three of the ALK-nega-
tive samples (Samples 48, 55, and 98, Additional file 1:
Table S2). In Sample 98, the KIF5B-RET fusion was
detected and subsequently confirmed by a TaqMan
assay. Samples 48 and 55 showed positive RET 3′/5′im-
balance results of 0.041 and 0.271, respectively. Subse-
quent FISH analysis of Sample 55 showed 10% split
signals in the tissue area used for extraction of RNA for
the AmpliSeq Fusion Lung Panel assay. Additional
material for confirmatory testing was not available for
Sample 48.
Lastly, a ROS1 fusion was detected with 83 fusion
reads in one of the ALK FISH-positive samples (Sample
8, Additional file 1: Table S2). The presence of two
fusion events is unlikely, and subsequent testing by RT-
PCR did not confirm the presence of this fusion.
Samples with low Total reads
Upon initial evaluation of the 138 clinical research sam-
ples, samples below the QC cut-off of 20,000 were
repeated with either 30 PCR cycles or simply re-pooling
prior to bead templating. Five of ten samples successfully
repeated, and those samples are included in the data
above. In the other five samples and in samples for
which repeat testing was not possible, reasons for failure
included insufficient RNA quantity (< 10 ng), degraded
RNA, and improper pooling of libraries.
Discussion
The advent of therapies targeting the fusion proteins
arising from ALK, ROS1, and RET gene fusions makes
the routine detection of these events important in
patients with lung adenocarcinoma. We have described
here an international, multi-institutional study using a
multiplex RT-PCR next generation sequencing-based
method that enables simultaneous detection of ALK,
RET, ROS1, and NTRK1 gene fusion transcripts in a
single assay. The simultaneous detection of these fusions
has important implications for turn-around-time and
cost. Further, it can be performed with very little input
RNA. This is particularly attractive for an assay targeted
at lung cancers, as these samples are often biopsies with
limited available tissue. Lung cancer fusions have
traditionally been detected using FISH, IHC, or RT-PCR.
While FISH is considered the gold standard, especially
for ALK testing due to the availability of an FDA-ap-
proved ALK FISH assay, FISH analysis for multiple tar-
gets per sample can be costly. Often these analyses are
done in step-wise fashion, which can reduce the overall
cost of performing multiple FISH assays, but potentially
extend the time needed to rule out all relevant gene re-
arrangements. Immunohistochemistry staining offers a
cheaper alternative; however, this methodology is sub-
jective, sometimes making interpretation difficult. [20]
RT-PCR, on the other hand, can offer precise detection
of fusions, including identification of both partner genes
and the exons involved. The main limitation of trad-
itional RT-PCR is that it typically focuses on only the
most common fusion events and is thus limited in de-
tecting rare exon combinations. [21]
In contrast to FISH or IHC, the detection of ALK,
ROS1, RET, and NTRK1 fusions are combined in a single
assay with the AmpliSeq design. From the 70 clinical
research samples that previously had been determined to
be ALK-negative by FISH, we detected two ROS1 fusions
and three RET fusions. Both of the ROS1 fusions and
two of RET fusions were confirmed to be positive by
orthogonal methods; tissue for additional testing was not
available for the third RET-positive sample. Further, the
detection of fusions by NGS offers a timely methodology
that can also be designed to accommodate the
Table 5 Discordant ALK clinical samples
Sample Laboratory FISH (rearranged cells) AmpliSeq result (n° reads) 3′-5′ imbalance IHC results
26 Viollier Positive (19%) Negative (136146) 0,0099 Positive
30 CROM Positive (20%) Negative (166403) 0,0008 2+
107 Queen’s Negative EML4(6a)-ALK(20) (1835387) 0,3179 Positive
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simultaneous detection of point mutations and inser-
tions and deletions in the DNA of relevant genes in a
single assay. Analysis of these types of mutations, par-
ticularly in EGFR and KRAS, is typically part of the
work-up of lung adenocarcinoma patients. Methods to
detect both DNA mutations and fusion events in a
timely manner are particularly important in these
patients due to the aggressive nature of the disease.
While combined analysis of DNA and RNA was not
the focus of this study, it is currently being performed
by many of the institutions that participated in this
study.
The methodology described in this paper relies on
RT-PCR for the initial amplification of fusion events;
however, the design of this assay circumvents a limita-
tion of traditional RT-PCR. The AmpliSeq Fusion Lung
Panel assay includes multiplexing of primers for 72 dif-
ferent fusion combinations and thus is not limited to
only the most common fusions. A second limitation of
traditional RT-PCR is that one must have previous
knowledge of all possible relevant fusions. The AmpliSeq
assay addresses this issue in two ways. First, during the
analysis of the sequenced reads, all reads that are initially
unaligned to the reference sequence are split in half and
allowed to re-align. This step fosters the detection of
novel fusions involving existing primers. Secondly, the
assay includes a method for detection fusions involving
unknown partners using the 3′/5′imbalance calculation.
This step analyzes the expression levels of the 3′ and 5′
ends of each driver gene. For genes involved in a fusion
event, the 3′ end of the gene is now under different
regulatory control and shows overexpression relative to
the 5′end of the gene. Another recently described
methodology using NanoString technology also exploits
this phenomenon of 3′overexpression. [22] That study
found that evaluation of the imbalance between 3′and
5′expression works relatively well for ALK and RET,
which are normally not expressed in lung tissue, but that
this calculation was more difficult for ROS1 as this gene
is normally expressed at high levels. Given that a positive
imbalance result is suggestive of a fusion event, but
alone does not identify an exact fusion, our suggestion
for the AmpliSeq assay is to use the imbalance calcula-
tion as a method for identifying possible fusions that
should be followed up with orthogonal testing methods
if desired.
Further analysis of discordant samples within our
study found that some samples had either low levels of
rearranged cells by FISH or discordant results between
FISH and IHC. One of the samples for which FISH
testing showed 10% rearranged cells, was positive for a
HIP1-ALK fusion upon repeat testing with the AmpliSeq
assay. The repeat result had fusion reads falling just
above the cut-off, while the initial negative result did
identify the same fusion but with a number of reads
falling below the cut-off, indicating the sample was likely
approaching the limit of detection for the assay. Dis-
cordance between ALK FISH and other methods has
been noted previously [23–25] and brings up the ques-
tion of a true “gold standard.” Three of the ALK
FISH-positive samples for which the AmpliSeq assay was
negative, were also negative by IHC. Additionally, we
found that five of the discordant samples displayed
single red signals by FISH. This phenomenon of a single
red signal represents a likely deletion of the 5′end of
ALK and is not unusual for this structural variant; how-
ever, previous studies have also shown a similar discord-
ance between ALK FISH-positive results displaying a
deletion of the 5′ALK probe and IHC [24] or PCR. [26]
The exact nature of these fusion events may be of inter-
est for future studies. We also observed discordant
results for one of the ALK FISH-negative samples. In
this case, the AmpliSeq assay identified an EML4-ALK
fusion with a high number of reads and the sample was
also positive by IHC. While this sample was officially
classified as an AmpliSeq “false positive,” it likely repre-
sents a true positive in which FISH testing failed to
detect the fusion.
A recent study using the AmpliSeq method for fusion
detection reported 100% concordance between this and
other methodologies. [27] It is unknown, but probable,
that the testing for this study was performed at a single
institution. The difference between a single or limited
institution study and a larger study (in this case, ten
institutions) may explain the difference in concordance
results between the Pfarr study [27] and the study
described here. The international, multi-institutional
nature of this study presented many challenges. Scoring
criteria between laboratories often varies even for
well-established reference methods, e.g., some samples in
this study were deemed FISH-positive, yet fell below the
cut-off of 15% used by other institutions. A lack of
concordance between multiple institutions for detection
of ALK rearrangements has been previously observed, [20,
28] and this phenomenon may have contributed to the
lower concordance of compared methods in this study. A
further challenge of the multi-institutional study included
a lack of material for follow up on discrepant samples, as
the samples were not only from the participating institu-
tions but in some cases were from additional laboratory
partners. However, we believe that the advantages of this
multi-institutional study far outweigh the disadvantages.
Reproducibility across different laboratories using cell line
mixtures was 100%, despite potential differences in
laboratory practices and personnel. Additionally, an inter-
national, multi-institutional study such as this allows for
the inclusion of more varied samples and more fully
explores the performance of the assay.
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Conclusion
The RT-PCR NGS assay described here offers many
advantages for laboratory testing in lung adenocarcin-
oma samples. This methodology allows detection of
multiple fusions in a single assay and can easily also be
multiplexed with detection of point mutations and small
insertions and deletions in genes such as KRAS and
EGFR that are also important in the work up of these
patients. The single-assay format potentially allows for
faster turn-around-time and lower cost than doing the
assays separately. Further, the small amount of input
RNA required is very advantageous for these samples.
However, the AmpliSeq assay primarily targets known
fusions. Inclusion of the 3′/5′imbalance calculation aims
to address this limitation, but could likely benefit from
further refinement of cut-offs values as more data is
generated by this assay. Lastly, efforts to periodically
update the primer pool as additional partner genes for
ALK, ROS1, RET, and NTRK1 fusions are identified
would aid in the continuing utility of this assay.
Additional file
Additional file 1: Table S1. RT-PCR Targets within the Ion AmpliSeq™
Lung Fusion Research Panel. A list of all targets in the multiplex PCR studied
– including targeted fusions (genes and exons), expression control genes,
and 3′and 5′regions. Table S2. ALK Clinical Samples. Table depicting details
on all ALK clinical research samples analyzed in the study. Table S3. ROS1
and RET clinical samples. Table depicting details on all ROS1 and RET clinical
research samples analyzed in the study. (DOCX 57 kb)
Abbreviations
FFPE: Formalin-fixed paraffin-embedded; FISH: Fluorescence in situ
hybridization; IHC: Immunohistochemistry; NGS: Next generation sequencing;
NSCLC: Non-small cell lung cancer; RT-PCR: Reverse transcriptase-polymerase
chain reaction
Acknowledgements
The authors wish to thank Xiao Zhang (Queen’s University, Kingston Ontario,
Canada), Miguel Silva (Ipatimup, Porto, Portugal) and Ana Justino (Ipatimup,
Porto, Portugal).
Funding
This work resulted from projects “Institute for Research and Innovation in
Health Sciences” (POCI-01-0145-FEDER-007274), “GenomePT” (POCI-01-0145-
FEDER-022184), “Advancing cancer research: from knowledge to application”
(NORTE-01-0145-FEDER-000029) supported by COMPETE 2020 - Operational
Programme for Competitiveness and Internationalisation (POCI), Norte
Portugal Regional Programme (NORTE 2020), Lisboa Portugal Regional
Operational Programme (Lisboa2020), Algarve Portugal Regional Operational
Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership
Agreement, through the European Regional Development Fund (ERDF), and
by FCT - Fundação para a Ciência e a Tecnologia (PTDC/DTP-PIC/2500/2014).
This work was supported by a grant from the Associazione Italiana per la
Ricerca sul Cancro (AIRC) to N. Normanno (Grant number: IG17135).
Availability of data and materials
The datasets used and analyzed during the current study are available from
the corresponding author on a reasonable request.
Author’s contributions
Study concept and design: IC, PLP, NN, OS, RP, KB, JC, CV, AM. Data acquisition,
analysis and interpretation: IC, AR, PLP, VB, RB, BT, NN, MJ, FM, HF, OS, KB, AS, JC,
CV, MB, KN, KS, AM, AR, SC, DC, HK. Drafting of the manuscript or revising it
critically for important intellectual content: IC, PLP, VB, NN, MJ, HF, AB, OS, AS,
JC, CV, JM, AM, SC. All authors have given final approval of the version to be
published.
Ethics approval and consent to participate
Samples were retrieved from the archives of the collaborating institutions
and de-identified. For the following institutions, the study was interpreted as
a service improvement not requiring specific research ethics committee
approval as stated in the EU Clinical Trials Directive (2001/20/EC): Radboud
university medical center, VIOLLIER (assay performed by Viollier, samples
mainly from University Hospital Basel and Luzerner Kantonsspital,
Switzerland), Applied Research on Cancer Centre (ARC-NET), University
Hospitals Coventry and Warwickshire (UHCW), Institut National de la Sante et
de la Recherche Medicale (INSERM), and Centro di Ricerche Oncologiche di
Mercogliano (CROM). Samples from the following institutions were used
under approved Institutional Review Board protocols: ARUP Laboratories
(ARUP Laboratories Ethics Committee approval 24,487), Queen’s University
(Health Sciences and Affiliated Teaching Hospitals Research Ethics Board ap-
proval 6,010,968), and Kinki University (Institutional Review Board of Kindai
University Faculty of Medicine approval 22–106). Samples from Ipatimup
were used in accordance with Article 19 (“DNA Banks and Other Biological
Products”) of Portuguese Law No. 12/2005 of 26 January (“Personal genetic
information and health information”).
Competing interests
Thermo Fisher Scientific provided reagents for this study to participating
laboratories at a discount. Travel funds were partially reimbursed for
consortium members to attend a group meeting. Authors R.P., V.B., and K.B.
are employed by Thermo Fisher Scientific. NN is a member of the editorial
board (Associate Editor) of this journal.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT,
USA. 2i3S - Instituto de Investigação e Inovação em Saúde, Universidade do
Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal. 3IPATIMUP - Institute
of Molecular Pathology and Immunology of the University of Porto, Rua
Alfredo Allen 208, 4200-135 Porto, Portugal. 4Medical Faculty of the
University of Porto, Porto, Portugal. 5Department of Pathology and Molecular
Medicine, Queen’s University, Kingston, ON, Canada. 6Thermo Fisher
Scientific, Austin, TX, USA. 7Laboratory of Pharmacogenomics, Centro di
Ricerche Oncologiche di Mercogliano (CROM)-Istituto Nazionale Tumori
“Fondazione G. Pascale”-IRCCS, Naples, Italy. 8Pathology Unit, Istituto
Nazionale Tumori “Fondazione G. Pascale”-IRCCS, Naples, Italy. 9Department
of Pathology, Radboud University Medical Center, Nijmegen, the
Netherlands. 10Viollier AG, Department of Genetics/Molecular Biology, Basel,
Switzerland. 11Department of Genome Biology, Kinki University Faculty of
Medicine, Osaka, Japan. 12ARC-NET: Centre for Applied Research on Cancer,
Department of Pathology and Diagnostic, University and Hospital Trust of
Verona, Verona, Italy. 13Department of Pathology, University Hospitals
Coventry and Warwickshire, Walsgrave, Coventry, UK. 14University Paris
Descartes, Paris, France. 15Biology Department, Assistance Publique-Hôpitaux
de Paris, European Georges Pompidou Hospital, Paris, France. 16Institute of
Pathology, University Hospital Basel, Basel, Switzerland. 17Luzerner
Kantonsspital, Luzern, Switzerland. 18Trinity Translational Medicine Institute
(TTMI), Trinity College Dublin, Dublin, Ireland. 19Department of Human
Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
20Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori “Fondazione G.
Pascale”-IRCCS, Naples, Italy. 21Centre for Sport, Exercise and Life Sciences,
Coventry University, Coventry, UK.
Received: 9 November 2017 Accepted: 9 August 2018
References
1. Cancer Genome Atlas Research N. Comprehensive molecular profiling of
lung adenocarcinoma. Nature. 2014;511(7511):543–50.
Vaughn et al. BMC Cancer  (2018) 18:828 Page 7 of 8
2. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez
C, Greulich H, Muzny DM, Morgan MB, et al. Somatic mutations affect key
pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069–75.
3. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II,
Chen H, Fujimoto J, Kugler K, Franklin WA, et al. Multi-institutional
oncogenic driver mutation analysis in lung adenocarcinoma: the lung
Cancer mutation consortium experience. J Thorac Oncol. 2015;10(5):768–77.
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S,
Watanabe H, Kurashina K, Hatanaka H, et al. Identification of the
transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature.
2007;448(7153):561–6.
5. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K,
Reeves C, Li Y, et al. Global survey of phosphotyrosine signaling identifies
oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203.
6. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto
H, Tsuta K, Furuta K, Shimada Y, et al. KIF5B-RET fusions in lung
adenocarcinoma. Nat Med. 2012;18(3):375–7.
7. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R,
Hamanaka W, Ninomiya H, Uehara H, et al. RET, ROS1 and ALK fusions in
lung cancer. Nat Med. 2012;18(3):378–81.
8. Li F, Feng Y, Fang R, Fang Z, Xia J, Han X, Liu XY, Chen H, Liu H, Ji H.
Identification of RET gene fusion by exon array analyses in “pan-negative”
lung cancer from never smokers. Cell Res. 2012;22(5):928–31.
9. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S,
Davies KD, Aisner DL, Pilling AB, et al. Oncogenic and drug-sensitive NTRK1
rearrangements in lung cancer. Nat Med. 2013;19(11):1469–72.
10. Uguen A, De Braekeleer M. ROS1 fusions in cancer: a review. Future Oncol.
2016;12(16):1911–28.
11. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi
HG, Kim J, Chiang D, Thomas R, et al. EML4-ALK fusion gene and efficacy of
an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–83.
12. Scarpino S, Rampioni Vinciguerra GL, Di Napoli A, Fochetti F, Uccini S, Iacono
D, Marchetti P, Ruco L. High prevalence of ALK+/ROS1+ cases in pulmonary
adenocarcinoma of adoloscents and young adults. Lung Cancer. 2016;97:95–8.
13. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, et al.
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive
study of common and fusion pattern-specific clinicopathologic, histologic and
cytologic features. Lung Cancer. 2014;84(2):121–6.
14. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and
RET fusions. Oncologist. 2013;18(7):865–75.
15. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR,
Linnoila RI, Matthews MJ, Bunn PA Jr, Carney D, et al. NCI-navy medical
oncology branch cell line data base. J Cell Biochem Suppl. 1996;24:32–91.
16. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD,
Gazdar AF. Allelotyping demonstrates common and distinct patterns of
chromosomal loss in human lung cancer types. Genes chromosomes
cancer. 1998;21(4):308–19.
17. Matsubara D, Kanai Y, Ishikawa S, Ohara S, Yoshimoto T, Sakatani T,
Oguni S, Tamura T, Kataoka H, Endo S, et al. Identification of CCDC6-
RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J
Thorac Oncol. 2012;7(12):1872–6.
18. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM,
Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, et al. Identifying and
targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res.
2012;18(17):4570–9.
19. Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R,
Amboldi N, Raddrizzani L, Milani A, Magnaghi P, et al. The TPM3-NTRK1
rearrangement is a recurring event in colorectal carcinoma and is
associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol.
2014;8(8):1495–507.
20. Tembuyser L, Tack V, Zwaenepoel K, Pauwels P, Miller K, Bubendorf L, Kerr K,
Schuuring E, Thunnissen E, Dequeker EM. The relevance of external quality
assessment for molecular testing for ALK positive non-small cell lung
cancer: results from two pilot rounds show room for optimization. PLoS
One. 2014;9(11):e112159.
21. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse
transcription-polymerase chain reaction, immunohistochemistry, and
fluorescence in situ hybridization methodologies for detection of
echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma
kinase fusion-positive non-small cell lung carcinoma: implications for
optimal clinical testing. Arch Pathol Lab Med. 2012;136(7):796–803.
22. Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim
HS, Cho BC, et al. A single-tube multiplexed assay for detecting ALK, ROS1,
and RET fusions in lung cancer. J Mol Diagn. 2014;16(2):229–43.
23. To KF, Tong JH, Yeung KS, Lung RW, Law PP, Chau SL, Kang W, Tong CY,
Chow C, Chan AW, et al. Detection of ALK rearrangement by
immunohistochemistry in lung adenocarcinoma and the identification of a
novel EML4-ALK variant. J Thorac Oncol. 2013;8(7):883–91.
24. Gao X, Sholl LM, Nishino M, Heng JC, Janne PA, Oxnard GR. Clinical
implications of variant ALK FISH rearrangement patterns. J Thorac Oncol.
2015;10(11):1648–52.
25. Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J,
Suh JH, Lipson D, et al. Comprehensive genomic profiling identifies a subset of
Crizotinib-responsive ALK-rearranged non-small cell lung Cancer not detected
by fluorescence in situ hybridization. Oncologist. 2016;21(6):762–70.
26. Dai Z, Kelly JC, Meloni-Ehrig A, Slovak ML, Boles D, Christacos NC, Bryke CR,
Schonberg SA, Otani-Rosa J, Pan Q, et al. Incidence and patterns of ALK
FISH abnormalities seen in a large unselected series of lung carcinomas.
Mol Cytogenet. 2012;5(1):44.
27. Pfarr N, Stenzinger A, Penzel R, Warth A, Dienemann H, Schirmacher P,
Weichert W, Endris V. High-throughput diagnostic profiling of clinically
actionable gene fusions in lung cancer. Genes chromosomes cancer.
2016;55(1):30–44.
28. Marchetti A, Barberis M, Papotti M, Rossi G, Franco R, Malatesta S, Buttitta F,
Ardizzoni A, Crino L, Gridelli C, et al. ALK rearrangement testing by FISH
analysis in non-small-cell lung cancer patients: results of the first italian
external quality assurance scheme. J Thorac Oncol. 2014;9(10):1470–6.
Vaughn et al. BMC Cancer  (2018) 18:828 Page 8 of 8
